Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3922197 | 0.85 | MAPT (0.53) | MAPTMAP2K1POLBTDP1L3MBTL1 | |
| SCHEMBL3922116 | 0.82 | KMT2A (0.52) | MAPTPOLBTDP1L3MBTL1KMT2A | |
| SCHEMBL3914048 | 0.80 | MAPT (0.52) | MAPTPOLBTDP1L3MBTL1KMT2A | |
| SCHEMBL22639695 | 0.80 | KMT2A (0.63) | MAPTPOLBTDP1L3MBTL1KMT2A | |
| SCHEMBL3915867 | 0.80 | TDP1 (0.60) | MAPTPOLBTDP1L3MBTL1EPHX2 | |
| SCHEMBL3913891 | 0.80 | MAPT (0.52) | MAPTPOLBTDP1L3MBTL1KMT2A | |
| SCHEMBL3913448 | 0.79 | MAPT (0.58) | MAPTMAP2K1POLBTDP1L3MBTL1 | |
| SCHEMBL3921843 | 0.79 | GAA (0.63) | MAPTPOLBTDP1L3MBTL1KMT2A | |
| SCHEMBL3914793 | 0.78 | KMT2A (0.55) | MAPTPOLBTDP1L3MBTL1KMT2A | |
| SCHEMBL3922029 | 0.78 | MAPT (0.58) | MAPTPOLBTDP1L3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060270720-A1 | Iminothiazolidinone derivatives as SFRP-1 antagonists | WYETH (US) | 2006-11-30 | — | — | US | claimed |
| WO-2006124887-A1 | IMINOTHIAZOLIDINONE DERIVATIVES AS SFRP-1 ANTAGONISTS | WYETH (US) | 2006-11-23 | — | — | WO | claimed |
| US-7563813-B2 | Iminothiazolidinone derivatives as SFRP-1 antagonists | WYETH (US) | 2009-07-21 | — | — | US | disclosed |
| US-20060270720-A1 | Iminothiazolidinone derivatives as SFRP-1 antagonists | WYETH (US) | 2006-11-30 | — | — | US | disclosed |
| WO-2006124887-A1 | IMINOTHIAZOLIDINONE DERIVATIVES AS SFRP-1 ANTAGONISTS | WYETH (US) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270720-A1 | Iminothiazolidinone derivatives as SFRP-1 antagonists | SFRP1, FZD7, DKK1 | MAPT 3137/4885MAP2K1 3535/4885POLB 4864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.